- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02422966
Paracetamol in Patent Ductus Arteriosus
Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although patency of the ductus arteriosus is essential for fetal circulation, the postnatal ductal closure is critical for postnatal circulatory adaptation. In premature infants the circulating prostaglandin levels are higher than at term, and respiratory difficulties may lead to a state of hypoxia, which contribute to the failure of the ductus closure. Recently, an incidental finding in one preterm infant led to look at paracetamol, one of the most common drugs available, as an alternative therapeutic approach to ductal closure. If paracetamol is proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable safety profile.
Although the recent results available in the literature demonstrates an highly success rate in ductal closure with paracetamol, all case studies are not powered to show efficacy of paracetamol for PDA closure. Further prospective randomized-controlled trials are needed to evaluate the efficacy of paracetamol versus ibuprofen for the closure of PDA.
If paracetamol is indeed proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable side effect profile. In order to test this hypothesis, a randomized, open label, parallel groups, comparator controlled, multicentre, prospective study is proposed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Firenze, Italy, 50134
- Azienda Ospedaliero Universitaria Careggi - Neonatologia e Terapia Intensiva Neonatale
-
Genova, Italy, 16147
- IRCCS "Giannina Gaslini" Genova - Patologia Neonatale e Terapia Intensiva Neonatale
-
Milano, Italy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico U.O. di Neonatologia e Terapia Intensiva Neonatale
-
Milano, Italy, 20154
- Azienda Ospedaliera Istituti Clinici di Perfezionamento (ICP) - Ospedale dei Bambini "Vittore Buzzi" Milano - Neonatologia
-
Roma, Italy, 00168
- Policlinico Gemelli Roma - UOC Neonatologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female preterm infants with no limitation of race.
- Gestational age 25(+0) - 31(+6) weeks.
- Age 24-72 hours.
Echocardiographic evidence of hemodynamically significant patent ductus arteriosus at the first 24-72 hours of life.
The diagnosis of hemodynamically significant PDA requiring treatment will be made by echocardiographic demonstration of a ductal left-to-right shunt, with a left atrium-to-aortic root ratio >1.3 or a ductal size >1.5 mm and excluding the cases in which the closing flow pattern suggests a restrictive PDA.
- Willingness of the parents/legally authorized representative/child to sign the Consent Informed Form.
Exclusion Criteria:
- Outborn patients.
- Major congenital anomalies, including but not limited to congenital heart defects, Down syndrome newborn and/or new born suffering from congenital anomalies diagnosed during the fetal period.
- Known positive HIV and/or known positive Hepatitis C Virus newborn's mother.
- Life threatening infection, complicated or not by multiple organ dysfunction and failure syndrome.
- Fetal hydrops.
- Pulmonary hypertension diagnosed in the first 24-48 hours of life by means of heart ultrasound when the presence of a right-to-left shunt through the foramen ovale or ductus arteriosus is demonstrated, or when the estimated pulmonary pressure, in terms of the tricuspid regurgitation jet, is greater than two-thirds of the systemic arterial pressure.
- Grade 3 or 4 intraventricular haemorrhage (IVH).
- Urine output <1 ml/kg of body weight/h during a 24 h collection period or urine output <0.5 ml/kg of body weight/h in case it is measured at 24 hours of life of newborn.
- Serum creatinine concentration > 1.5 mg/dl (132 μmol/l).
- Platelet count < 50,000/mm3.
- Major bleeding, as revealed by hematuria, or blood in the endotracheal aspirate, gastric aspirate, or stools, or consistent oozing of blood from puncture sites.
Severe liver failure, defined as elevated liver enzymes (ALT/Glutamate-Pyruvate Transaminase and Aspartate aminotransferase/GOT) > 2 times the upper boundary of the normal range. For this kind of population the following normal ranges will be considered [Rosenthal, 1997]:
- ALT/Glutamate-pyruvate transaminase: 6-50 U/L
- Aspartate aminotransferase/GOT: 35-140 U/L
- Medical need of administering other Nonsteroidal Antiinflammatory Drug (NSAID) different from ibuprofen.
- Participation to another trial involving any investigational drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paracetamol
Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
|
Other Names:
|
Active Comparator: Ibuprofen
Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
success rate in closing PDA using paracetamol in comparison to ibuprofen.
Time Frame: at Visit 3 (day 3).
|
assessed echocardiographically.
|
at Visit 3 (day 3).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of re-openings.
Time Frame: at Follow-up 3 (day 30).
|
assessed echocardiographically.
|
at Follow-up 3 (day 30).
|
success rate in closing PDA after the second treatment course of ibuprofen as rescue medication.
Time Frame: at Visit 6 (day 6).
|
assessed echocardiographically.
|
at Visit 6 (day 6).
|
success rate of closing PDA after the first day of the first treatment course.
Time Frame: at Visit 1 (day 1).
|
assessed echocardiographically.
|
at Visit 1 (day 1).
|
success rate of closing PDA after the second day of the first treatment course.
Time Frame: at Visit 2 (day 2).
|
assessed echocardiographically.
|
at Visit 2 (day 2).
|
incidence of surgical ligation.
Time Frame: at Follow-up 3 (day 30).
|
at Follow-up 3 (day 30).
|
|
incidence of renal failure, liver failure and gastrointestinal complications (including isolated intestinal perforation).
Time Frame: at Follow-up 3 (day 30).
|
assessed by laboratory analysis.
|
at Follow-up 3 (day 30).
|
incidence of death,
Time Frame: at Follow-up 3 (day 30).
|
at Follow-up 3 (day 30).
|
|
incidence of death.
Time Frame: at Follow-up 4 (40 weeks post-conception).
|
at Follow-up 4 (40 weeks post-conception).
|
|
incidence of sepsis.
Time Frame: at Follow-up 3 (day 30).
|
at Follow-up 3 (day 30).
|
|
hospital-stay duration in Neonatal Intensive Care Unit.
Time Frame: at Follow-up 4 (40 weeks post-conception).
|
at Follow-up 4 (40 weeks post-conception).
|
|
occurrence of adverse effects.
Time Frame: at Follow-up 3 (day 30).
|
at Follow-up 3 (day 30).
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Dani C, Lista G, Bianchi S, Mosca F, Schena F, Ramenghi L, Zecca E, Vento G, Poggi C, Leonardi V, Minghetti D, Rosignoli MT, Calisti F, Comandini A, Cattaneo A, Lipone P. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. Eur J Pediatr. 2021 Mar;180(3):807-816. doi: 10.1007/s00431-020-03780-8. Epub 2020 Sep 4.
- Dani C, Poggi C, Mosca F, Schena F, Lista G, Ramenghi L, Romagnoli C, Salvatori E, Rosignoli MT, Lipone P, Comandini A. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. Trials. 2016 Apr 2;17:182. doi: 10.1186/s13063-016-1294-4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Ductus Arteriosus, Patent
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
- 044CF13273
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ductus Arteriosus, Patent
-
PFM Medical, IncBright Research PartnersCompleted
-
Abbott Medical DevicesCompletedPatent Ductus Arteriosus (PDA)United States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPatent Ductus Arteriosus | Patent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus - Delayed ClosureItaly, United Kingdom
-
Nada YoussefCompletedPatent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus Conservative ManagementEgypt
-
Ankara UniversityCompletedPatent Ductus Arteriosus in Preterm InfantsTurkey
-
Abbott Medical DevicesNo longer availablePatent | Ductus | Arteriosus
-
University of FlorenceCompletedDuctus Arteriosus, PatentItaly
-
National Taiwan University HospitalCompletedPatent Ductus Arteriosus
-
Rambam Health Care CampusCompletedDuctus Arteriosus, PatentIsrael
-
Soha mahmoud Hussien mahdyAssiut UniversityNot yet recruiting
Clinical Trials on Paracetamol
-
GlaxoSmithKlineCompleted
-
University of HelsinkiFoundation for Paediatric Research, FinlandCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedHealthy SubjectsUnited States
-
Kamuzu University of Health SciencesCompleted
-
Baxter Healthcare CorporationCompletedPain, PostoperativeUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompleted